Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion

JCO Precis Oncol. 2022 Nov:6:e2200263. doi: 10.1200/PO.22.00263.

Subotheni Thavaneswaran^{1

2

3}, Wei Yen Chan¹, Ray Asghari⁴, John P Grady², Maegan Deegan⁵, Valerie M Jansen⁵, David M Thomas^{1

2}

¹ The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
² Garvan Institute of Medical Research, St Vincent's Clinical School, Faculty of Medicine, UNSW, Darlinghurst, NSW, Australia.
³ NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
⁴ Cancer Therapy Centre, Bankstown-Lidcombe Hospital, Bankstown, NSW, Australia.
⁵ Elevation Oncology, Inc, New York, NY.

No abstract available

Publication types